K.o slashed.benhavn .O slashed., Denmark

Keld Kjeldsen


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Keld Kjeldsen

Introduction

Keld Kjeldsen is an accomplished inventor based in Copenhagen, Denmark. He is known for his significant contribution to the medical field through his work on organ rejection markers. With a notable patent to his name, Kjeldsen stands out in the realm of innovation and invention.

Latest Patents

Keld Kjeldsen holds a patent for "Markers for Organ Rejection." This invention addresses a critical issue in organ transplantation, providing a means to identify organ rejection early, which can significantly improve patient outcomes. His innovative research showcases the intersection of science and technology in solving pressing medical challenges.

Career Highlights

Kjeldsen's career is rooted in academic excellence. He is associated with Université Catholique de Louvain, where he has conducted extensive research in the field of medical science. His commitment to advancing knowledge and practical applications in his field is evident through his solitary patent and ongoing projects.

Collaborations

Throughout his career, Keld Kjeldsen has collaborated with esteemed colleagues such as Stig Haunso and Jørn Carlsen. These partnerships have enriched his research endeavors and contributed to the successful development of his patent. Working collaboratively underscores the importance of teamwork in the process of innovation.

Conclusion

In summary, Keld Kjeldsen is a remarkable inventor whose work on organ rejection markers exemplifies the potential of targeted innovations in healthcare. His association with Université Catholique de Louvain and collaborations with other skilled professionals illustrate his dedication to advancing medical technology. The impact of his innovations will likely resonate in the medical community for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…